| Price and Volume | |
|---|---|
| Recent Price | 0.31 |
| 52 Week High | 2.68 |
| 52 Week Low | 0.29 |
| Avg. Daily Vol. (Mil) | 0.20 |
| Beta (3 year) | 3.78 |
| Share Related Items | |
| Mkt Cap (Mil) | 14.67 |
| Shares Out (Mil) | 48.11 |
| Float (Mil) | 41.48 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.40 |
| Current Ratio | 1.60 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 0.89 |
| Price/Book | 2.82 |
| Price/Cash Flow | -0.30 |
| Per Share Data | |
| Earnings | -0.94 |
| Sales | 0.34 |
| Book Value | 0.11 |
| Cash Flow | -0.91 |
| Business Summary | |
|---|---|
| Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. | |
| General Information | |
| 3570 Carmel Mountain Road
Suite 100 San Diego, CA 92130 |
|
| www.somaxon.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 36 | |
| CEO: Richard W. Pascoe | |
| Short Interest | |
| Current Month (Mil) | 3.30 |
| Previous Month (Mil) | 3.40 |
| Short Interest Ratio (Days) | 11.10 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -359.10 |
| Return on Investments | -851.00 |
| Profitability | |
| Gross Margin | 90.10 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,434.09 | 1,315.50 | 2,842.81 | 16.27 |
Oil *
103.29
|
|
DOWN
146.60 |
DOWN
16.92 |
DOWN
28.18 |
DOWN
1.04 |
10 Yr
1.63%
SPDR Gold
151.95
|
|
-1.17%
|
-1.27%
|
-0.98%
|
-6.01%
|
Data delayed 20 minutes |
Connect with TheStreet